B & T Capital Management DBA Alpha Capital Management Increases Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

B & T Capital Management DBA Alpha Capital Management increased its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 154.8% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 3,147 shares of the biopharmaceutical company's stock after acquiring an additional 1,912 shares during the period. B & T Capital Management DBA Alpha Capital Management's holdings in Regeneron Pharmaceuticals were worth $2,242,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. Adirondack Trust Co. lifted its holdings in Regeneron Pharmaceuticals by 2.4% during the 3rd quarter. Adirondack Trust Co. now owns 431 shares of the biopharmaceutical company's stock worth $453,000 after buying an additional 10 shares during the last quarter. UMB Bank n.a. raised its position in shares of Regeneron Pharmaceuticals by 1.1% during the 3rd quarter. UMB Bank n.a. now owns 908 shares of the biopharmaceutical company's stock worth $955,000 after acquiring an additional 10 shares in the last quarter. Trust Co. of Vermont lifted its stake in Regeneron Pharmaceuticals by 8.3% during the third quarter. Trust Co. of Vermont now owns 157 shares of the biopharmaceutical company's stock worth $165,000 after purchasing an additional 12 shares during the last quarter. Brighton Jones LLC increased its stake in Regeneron Pharmaceuticals by 1.5% in the second quarter. Brighton Jones LLC now owns 920 shares of the biopharmaceutical company's stock valued at $967,000 after purchasing an additional 14 shares during the last quarter. Finally, Nvwm LLC raised its holdings in Regeneron Pharmaceuticals by 1.4% during the third quarter. Nvwm LLC now owns 988 shares of the biopharmaceutical company's stock worth $1,039,000 after purchasing an additional 14 shares in the last quarter. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Several research analysts have recently issued reports on REGN shares. Morgan Stanley lowered their target price on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an "overweight" rating for the company in a report on Friday, November 1st. Leerink Partners restated a "market perform" rating and issued a $1,077.00 price objective (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. BMO Capital Markets cut their target price on Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an "outperform" rating on the stock in a research report on Friday, November 1st. Royal Bank of Canada decreased their target price on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a research report on Friday, November 1st. Finally, Piper Sandler cut their price target on Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating on the stock in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, seven have given a hold rating, fifteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $1,015.38.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $11.65 during trading hours on Friday, hitting $681.58. 1,107,622 shares of the stock were exchanged, compared to its average volume of 678,713. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The company has a market cap of $74.90 billion, a price-to-earnings ratio of 16.87, a price-to-earnings-growth ratio of 1.60 and a beta of 0.10. Regeneron Pharmaceuticals, Inc. has a 12-month low of $666.25 and a 12-month high of $1,211.20. The stock has a 50-day moving average of $738.60 and a 200 day moving average of $949.32.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.